OpenNashEarnings

Alnylam (ALNY) · Biotechnology

Alnylam Q3 2026 earnings: summary, key numbers & outlook

Results filed 29 Oct 2026 · Quarter ended 30 Sep 2026

Slides (33 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Alnylam enlarged its TRITON-CM nucresiran trial to about 2,250 patients, keeping a 2030 ATTR-CM launch, while AMVUTTRA's cardiomyopathy launch kept driving TTR growth.

AMVUTTRA's ATTR-CM launch remained the main driver of demand. U.S. prescriptions grew about 70% year over year, and more than 2,000 new prescribers have been added since March 2025. Abroad, ATTR-CM launches in Japan, Germany and Italy added to growth. New HELIOS-B analyses showed consistent benefit with or without baseline tafamidis. Brezosiran, for Huntington's disease, showed a 60-64% mean reduction of mutant huntingtin in spinal fluid.

Management wants durable TTR leadership through nucresiran, plus a second growth platform beyond TTR through brezosiran, mivelsiran and other RNAi programs. The tension is access. A proposed CMS change to 340B reimbursement could take effect January 1, 2027, and Alnylam is relying on contracting and alternative care sites to protect access. TRITON-CM's larger size also adds execution risk for the 2030 launch.

Slides & documents

Open the slide deck (PDF, 33 pages) ↗

Alnylam Q3 2026 slide deck, page 1Alnylam Q3 2026 slide deck, page 2Alnylam Q3 2026 slide deck, page 3Alnylam Q3 2026 slide deck, page 4Alnylam Q3 2026 slide deck, page 5Alnylam Q3 2026 slide deck, page 6

Showing the first 6 of 33 pages.

SEC filing

Key numbers

Total revenues · GAAP
$1.5B

17% vs Q3 2025

Net income · GAAP
$2.2B

vs $292,683 in Q3 2025

Diluted EPS · GAAP
$15.72

vs $2.14 in Q3 2025

Non-GAAP diluted EPS · non-GAAP
$16.26

up 410% from a year ago

GAAP income from operations · GAAP
$345.8M

down 6% from a year ago

Total net product revenues
$1,292 Million

52% growth compared with Q3 2025

Segment or metricValueChange
AMVUTTRA net product revenues$1.1B65% vs Q3 2025
ONPATTRO net product revenues19.6M(50)% vs Q3 2025
GIVLAARI net product revenues89.5M21% vs Q3 2025
OXLUMO net product revenues52.5M(1)% vs Q3 2025
Royalty revenue94.7M105% vs Q3 2025
Where each number comes from
  • Total revenues: “Total revenues | $1,458,086 | $1,249,026 | 17% GAAP Income from operations | $345,798 | $367,982 | (6)%”
  • Net income: “GAAP Net income | $2,167,335 | $292,683 | * Non-GAAP Net income | $2,241,910 | $437,779 | 412%”
  • Diluted EPS: “GAAP Net income per common share — diluted | $15.72 | $2.14 | * Non-GAAP Net income per common share — basic | $16.75 | $3.33 | 403%”
  • Non-GAAP diluted EPS: “Non-GAAP Net income per common share — diluted | $16.26 | $3.19 | 410% * Indicates the percentage change period over period is greater than 500%”
  • GAAP income from operations: “Total revenues | $1,458,086 | $1,249,026 | 17% GAAP Income from operations | $345,798 | $367,982 | (6)% Non-GAAP Income from operations | $424,916 | $476,193 | (11)%”
  • Total net product revenues: “Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million”
  • AMVUTTRA net product revenues: “Net product revenues: AMVUTTRA | $1,130,363 | $685,303 | 65% | 66% ONPATTRO | 19,596 | 39,075 | (50)% | (50)% Total TTR net product revenues”
  • ONPATTRO net product revenues: “AMVUTTRA | $1,130,363 | $685,303 | 65% | 66% ONPATTRO | 19,596 | 39,075 | (50)% | (50)% Total TTR net product revenues”
  • GIVLAARI net product revenues: “Total TTR net product revenues | 1,149,959 | 724,378 | 59% | 60% GIVLAARI | 89,487 | 73,874 | 21% | 22% OXLUMO | 52,500 | 52,830 | (1)% | —%”
  • OXLUMO net product revenues: “GIVLAARI | 89,487 | 73,874 | 21% | 22% OXLUMO | 52,500 | 52,830 | (1)% | —% Total Rare net product revenues”
  • Royalty revenue: “Total net revenues from collaborations | 71,476 | 351,742 | (80)% | (80)% Royalty revenue | 94,664 | 46,202 | 105% | 105% Total revenues”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ3 2026vs year agovs last quarter
Revenue$1.5B+16.7%+12.9%
Operating income$345.8M−6.0%+49.4%
Net income$2.2B+640.5%+1217.6%
Diluted EPS$15.72+634.6%+1199.2%
Free cash flow$271.2M−4.8%—
Operating margin23.7%−5.8 pts+5.8 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Total TTR net product revenuesFY 2026$4,200 million - $4,500 million
Total Rare net product revenuesFY 2026$500 million - $600 million
Total net product revenuesFY 2026$4,700 million - $5,100 million
Net revenues from collaborations and royaltiesFY 2026$575 million - $625 million
Non-GAAP R&D and SG&A expensesFY 2026$2,700 million - $2,800 million

Key takeaways

  1. TRITON-CM enrollment expanded without delaying launch

    Alnylam is raising target enrollment from 1,750 to approximately 2,250 patients, enriched for early disease and sized for conservative event rates. It still expects a nucresiran ATTR-CM launch by 2030, so the larger trial is meant to improve the chance of success.

  2. AMVUTTRA prescriber base keeps broadening

    U.S. ATTR-CM category prescriptions grew about 70% year over year, and more than 2,000 new unique AMVUTTRA prescribers have been added since March 2025. Alnylam says about 80% of ATTR-CM patients remain untreated, so the growth is still early.

  3. HELIOS-B data back first-line positioning

    A subgroup analysis showed consistent benefit with or without baseline tafamidis use, and further analyses covered multisystemic manifestations and sex. This supports the case for vutrisiran as a first-line ATTR-CM treatment against competing therapies.

  4. Brezosiran opens a path beyond TTR

    Phase 1 data showed a 60-64% mean CSF mHTT reduction at month 3 in the highest dose group, with an encouraging safety profile. A placebo-controlled pivotal study is planned for 2027, pending regulatory alignment, in collaboration with Regeneron.

  5. 340B reimbursement change is a access risk

    A proposed CMS rule would cut hospital outpatient reimbursement for Part B medicines bought under 340B, effective January 1, 2027 if implemented. Alnylam plans to respond through health system contracting and alternative sites of care such as home care and third-party infusion clinics.

Charts

Revenue$1.5B+16.7% y/yQ3 2026
Q4 2024: $593.2M (worked out from the annual figure)Q4 ’24$593.2MQ1 2025: $594.2MQ1 ’25$594.2MQ2 2025: $773.7MQ2 ’25$773.7MQ3 2025: $1.2BQ3 ’25$1.2BQ4 2025: $1.1B (worked out from the annual figure)Q4 ’25$1.1BQ2 2026: $1.3BQ2 ’26$1.3BQ3 2026: $1.5BQ3 ’26$1.5B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$593.2M *
Q1 2025$594.2M
Q2 2025$773.7M
Q3 2025$1.2B
Q4 2025$1.1B *
Q2 2026$1.3B
Q3 2026$1.5B
Diluted EPS (GAAP)$15.72+634.6% y/yQ3 2026
Q1 2025: -$0.14Q1 ’25-$0.14Q2 2025: -$0.55Q2 ’25-$0.55Q3 2025: $2.14Q3 ’25$2.14Q2 2026: $1.21Q2 ’26$1.21Q3 2026: $15.72Q3 ’26$15.72
Data
Q1 2025-$0.14
Q2 2025-$0.55
Q3 2025$2.14
Q2 2026$1.21
Q3 2026$15.72

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin23.7%−5.8 pts y/yQ3 2026
Q4 2024: -17.7%Q4 ’24-17.7%Q1 2025: 3.0%Q1 ’253.0%Q2 2025: -2.1%Q2 ’25-2.1%Q3 2025: 29.5%Q3 ’2529.5%Q4 2025: 12.0%Q4 ’2512.0%Q2 2026: 17.9%Q2 ’2617.9%Q3 2026: 23.7%Q3 ’2623.7%
Data
Q4 2024-17.7%
Q1 20253.0%
Q2 2025-2.1%
Q3 202529.5%
Q4 202512.0%
Q2 202617.9%
Q3 202623.7%
Free cash flow$271.2M−4.8% y/yQ3 2026
Q4 2024: -$103.8MQ4 ’24-$103.8MQ1 2025: -$127.3MQ1 ’25-$127.3MQ2 2025: $113.5MQ2 ’25$113.5MQ3 2025: $284.7MQ3 ’25$284.7MQ4 2025: $194.4MQ4 ’25$194.4MQ3 2026: $271.2MQ3 ’26$271.2M
Data
Q4 2024-$103.8M
Q1 2025-$127.3M
Q2 2025$113.5M
Q3 2025$284.7M
Q4 2025$194.4M
Q3 2026$271.2M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What changed for the TRITON-CM nucresiran trial?

Target enrollment rose from 1,750 to approximately 2,250 patients, enriched for early disease to ensure adequate power. Alnylam still expects an ATTR-CM launch by 2030, assuming positive data and approval.

How is AMVUTTRA demand developing in the U.S.?

ATTR-CM category prescriptions grew about 70% year over year, and AMVUTTRA reached a 37% total prescription share in ATTR. More than 2,000 new unique prescribers have been added since March 2025.

What did Alnylam report for brezosiran in Huntington's disease?

Phase 1 patients showed a 60-64% mean CSF mHTT reduction at month 3 in the highest dose group, with a good safety profile so far. A placebo-controlled pivotal study is planned for 2027, pending regulatory alignment.

What is the risk from 340B changes?

A proposed CMS rule would reduce hospital outpatient reimbursement for Part B medicines acquired through 340B, effective January 1, 2027 if implemented. Alnylam points to health system contracting and alternative care sites to mitigate patient access risk.

Is Alnylam changing its 2026 guidance?

No. It reiterated full-year 2026 total net product revenue guidance of $4,700 million - $5,100 million and said it is on track to achieve its 2026 financial guidance.

Call recording

Call recording on YouTube ↗. Official replay ↗.